Most Read

The framework will enable pharmaceutical partners to access integrated data packages combining system-level testing and performance data for injectable therapies. Aptar Pharma stated that demand for earlier insight

This first-in-class complement inhibitor received the approval through a priority review process after its initial accelerated approval in August 2024 for reducing proteinuria in primary IgAN. Results from

The Department of Health and Social Care (DHSC) will consider the guidance before making any decisions about adjustments to the NHS Meningitis B (MenB) vaccination schedule. This latest

Known as Telix Manufacturing Solutions North Melbourne (TMSNM), the site is described as the country’s first purpose-built facility to combine radiochemistry laboratories, clinical manufacturing, patient dose administration, and

HBM7575/SKB575 is designed to target thymic stromal lymphopoietin (TSLP) as well as an undisclosed antigen. The long-acting antibody uses a dual mechanism of action. It works to block

The decision is based on results from the Phase III MAJESTY study, which indicated that Gazyva/Gazyvaro achieved a higher rate of complete remission at two years compared to

IBI355 is an Fc-silent, third-generation anti-CD40L antibody that is expected to advance to Phase II trials for immunoglobulin G4 (IgG4)-related disease. Spero plans to launch a global Phase

The agreement grants Novartis access to Chai Discovery’s latest AI models, including its Chai-3 model, to support antibody discovery efforts across a range of therapeutic targets. The partnership

SBT-77-7101 is described as an autologous CAR-Treg cell therapy currently in Phase I clinical development to treat patients with poly-refractory rheumatoid arthritis (RA). These patients with RA have